Foundation Fighting Blindness
About Foundation Fighting Blindness
The Foundation Fighting Blindness Inc. Clinical Research Institute (FFB CRI) is committed to developing treatments and cures of rare genetic diseases of the retina, including retinitis pigmentosa, macular degeneration, Usher syndrome, Stargardt disease, and related conditions. These diseases, which affect more than 10 million Americans and millions more throughout the world, often lead to severe vision loss or complete blindness. Working with preeminent scientists, the FFB has funded breakthroughs in gene therapy, stem cells, and bionic retinas, providing a historic opportunity for a promising new era in human clinical trials. We are the largest non-governmental source of research funds for inherited retinal degenerative diseases.
The FFB CRI works to accelerate the translation of laboratory-based research into clinical trials for treatments and cures of these degenerative diseases. As the translational arm of the Foundation Fighting Blindness, it is the bridge between scientific, clinical, governmental, pharmaceutical, and financial communities to advance clinical trials of new treatments. The FFB CRI invests funds to support Phase 1 and Phase 2 clinical trials to expedite the commercialization of treatments for the entire spectrum of inherited retinal diseases, and also provides assistance for the management of clinical trials and subsequent commercialization.
Thanks to research advances made possible by FFB and research-funding organizations around the world, more clinical trials for therapies of inherited retinal diseases are underway than ever before (currently 24 in Phase 1/2; 1 in Phase 3). While not all will gain regulatory approval, the momentum in clinical development provides real promise for saving and restoring vision of those affected.